Search research articles
Contact Us
Filters
Showing results (101-110 of 173) with videos related to
Page
of 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 21, 2025
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
Joaquim Bosch-Barrera, Purificación Estévez-García, Paloma Martín-Martorell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Stephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Page
of 18
Search research articles
Search
Showing results (101-110 of 173) with videos related to
Sort By:
Page
of 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2020
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro, Nicoletta Colombo, Giovanni Scambia, et al.
Lung Cancer (Amsterdam, Netherlands)
|
February 21, 2025
ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer
Joaquim Bosch-Barrera, Purificación Estévez-García, Paloma Martín-Martorell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 16, 2023
Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
Stephanie Lheureux, Stephenie D Prokopec, Leslie E Oldfield, et al.
The Lancet. Oncology
|
February 6, 2025
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Amit M Oza, Alla Lisyanskaya, Alexander Fedenko, et al.
JAMA Oncology
|
October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T Kwan, Amit M Oza, Anna V Tinker, et al.
Gynecologic Oncology
|
August 28, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer
David M O'Malley, Ana Oaknin, Bradley J Monk, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
The Lancet. Oncology
|
April 16, 2021
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Michael Friedlander, Kathleen N Moore, Nicoletta Colombo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2022
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 1, 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
Bradley J Monk, Robert L Coleman, Keiichi Fujiwara, et al.
Page
of 18